Recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion groupClinical protocol
In ongoing clinical trials (multipeptide loaded cytokine matured moDC +/- CD40L activation in >60 pat.) we have obtained valuable information with high impact on future DC-trials:
1) the presence of 2% DMSO in the thawed final vaccine has no negative impact on the quantity and quality of induced immune responses; thus thawed DMSO containing vials do not have to be centrifuged, but simply diluted;
2) class I peptide loaded cytokine matured DC induce de novo or expand preexisting CD8+ T cell IFN gamma responses in the majority of melanoma patients (>70%), surprisingly without the need for class II peptide loading for T cell help;
3) a statistical analysis of the whole group of vaccinated melanoma patients showed statistically significant DC induced responses towards the antigens gp100.A2, NY-ESO1.A2, MAGE-3.DR11 and MAGE3.DP4.
This information will help finalizing the recommendations for vaccine standardization and conduct of DC-trials addressing clinical variables identified in the core discussion group.
- biomaterial type
- Dimethyl sulfoxide,
- T cell,
- melanoma antigen MAGE-3,
- gp100 antigen,
- CD40 ligand,
- Interferon gamma,
- Homo sapiens